ANN ARBOR STAGE II DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for ANN ARBOR STAGE II DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE II DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE II DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for HIV patients with aggressive lymphoma: targeted drug combo shows promise
Disease control OngoingThis early-stage trial tests a new drug, ibrutinib, combined with standard chemotherapy for people with HIV who have advanced diffuse large B-cell lymphoma. The goal is to find the safest dose and see if the combination can better control the cancer. About 46 participants will be…
Matched conditions: ANN ARBOR STAGE II DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:33 UTC
-
Could adding lenalidomide boost lymphoma treatment?
Disease control OngoingThis study compares two treatments for people with a fast-growing type of lymphoma (diffuse large B-cell lymphoma). One group gets standard chemo plus rituximab, and the other gets the same plus an extra drug called lenalidomide. The goal is to see if adding lenalidomide helps ke…
Matched conditions: ANN ARBOR STAGE II DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:29 UTC
-
New hope for aggressive lymphoma: targeted drug combo shows promise
Disease control OngoingThis study tests a new drug called parsaclisib added to standard chemotherapy (R-CHOP) for people with newly diagnosed, high-risk diffuse large B-cell lymphoma. The goal is to find the safest dose and see if the combination improves treatment response. About 50 adults will take p…
Matched conditions: ANN ARBOR STAGE II DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 08:28 UTC